Unlock instant, AI-driven research and patent intelligence for your innovation.

Azithromycin for treatment of skin disorders

A technology for azithromycin and skin diseases, which is applied in the field of systemic drug therapy for the treatment of dermatological diseases, can solve problems such as not being very effective, and achieve the effect of improving safety

Inactive Publication Date: 2010-09-15
DOW PHARMA SCI INC
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Therefore, therapies aimed solely at reducing the population of P. acnes microorganisms are generally not very effective in the long-term treatment of acne

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Azithromycin for treatment of skin disorders
  • Azithromycin for treatment of skin disorders
  • Azithromycin for treatment of skin disorders

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0077] Example 1 - Azithromycin Levels in Plasma

[0078] Plasma levels of azithromycin were determined as follows. Thirty-nine patients were randomized into one of three treatment groups. Each patient received oral azithromycin 40 mg (n=13), 80 mg (n=11) or 120 mg (n=15) daily. After the initial dose on day 0, a second dose was administered until 72 hours later to enable measurement of plasma levels on a single dose basis, as well as determination of pharmacokinetic parameters. Blood samples were collected from each patient at 0 (pre-dose), 1, 2, 3, 4, 6, 8, 24, 48 and 72 hours after the initial oral dose. After 72 hours, each patient received azithromycin daily for the remainder of the six weeks (42 days). Blood samples were also taken at 0 (pre-dose) and 3 hours post-dose on day 21 and at 0, 1 , 2, 3, 4, 6, 8 and 24 hours after the last dose on day 42. After collection, plasma samples from blood samples were stored at -20°C or below until processed and analyzed.

[007...

Embodiment 2

[0087] Example 2 - Azithromycin Levels in Sebum

[0088] use (CuDerm Corporation, Dallas TX) collected sebum from the subjects of Example 1. On days 0, 21, 42, and 70 of the study, three patches were placed on each subject's facial skin on the forehead, left and right cheeks Apply the sheet and let it stay for 30-40 minutes. The patch was then removed, folded in half with the adhesive side inward, placed in an airtight glass bottle and frozen at -20°C to -70°C.

[0089] A 250:150:100:0.5:0.1 mixture of ethyl acetate, methanol, acetonitrile, formic acid, and morpholine was used as the mobile phase to extract each Paste the sebum collected in the patch. Extracts were fortified with internal standard azaerythromycin. Aliquots of 5 microliters are injected into a suitable high pressure liquid chromatography (HPLC) equipped with suitable mass spectrometry-mass detection, such as a Sciex API 3000 LC-MS-MS. The HPLC column used was PVA-Sil, 5 micron, 4.0 x 50 mm column. The...

Embodiment 3

[0098] Example 3 - Azithromycin Levels in Skin

[0099] On study days 0, 21, 42, and 70, normalized hair follicle biopsy samples representing dermal pilosebaceous units were obtained from the upper back of each subject in Example 1 . These samples were analyzed to determine the tissue levels of azithromycin in each biopsy. The results are shown in Table 3.

[0100]

[0101] table 3

[0102] As shown in Table 3, the median amount of azithromycin in skin hair follicle biopsy samples increased with increasing doses of azithromycin. The difference in the amount of azithromycin obtained between the doses of 80 mg / day and 120 mg / day was much smaller than the difference in the amount of azithromycin obtained between the doses of 40 mg / day and 80 mg / day. The data suggest that the skin, particularly the pilosebaceous unit revealed by follicle biopsy, is saturated with azithromycin at doses of 80-120 mg / day. From this data, it was inferred that the skin was saturated with azithro...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Azithromycin has increased efficacy in treating acne and other skin conditions when administered systemically at low doses, below those previously known to produce a clinical antibiotic effect.

Description

field of invention [0001] The present invention relates to the field of treatment of dermatological conditions with systemic drug therapy. More specifically, the present invention relates to the treatment of skin disorders, such as acne, that respond to treatment with systemically administered azithromycin. Background of the invention [0002] The skin is constantly afflicted by various inflammatory and non-inflammatory conditions. One such disease is acne, a common disease characterized by several types of lesions. Generally affected areas are those areas of skin with the largest, most numerous and most active sebaceous glands. Lesions associated with acne are generally classified as non-inflammatory or inflammatory. Noninflammatory lesions include comedones. Comedones show up in two forms, open and closed. Acne is thought to be caused by abnormal hair follicle differentiation. Abnormally exfoliated cells (keratinocytes), which are not shed and expelled through the fo...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7052
CPCA61K9/4891A61K9/2886A61K31/7052A61K9/2081A61K9/4858A61K9/2846A61P17/00A61P17/10A61P31/00A61P31/04
Inventor G·J·道B·乔杜里D·W·奥斯本B·卡尔瓦雷塞
Owner DOW PHARMA SCI INC